<DOC>
	<DOCNO>NCT02398019</DOCNO>
	<brief_summary>Patients require cardiopulmonary bypass ( CPB ) surgery present systemic inflammatory response syndrome ( SIRS ) due blood cell activation cytokine release circulation . SIRS lead organ dysfunction due hemodynamic compromise ( vasodilatation plus leak syndrome ) and/or cytokine mediate cell injury . Renal dysfunction major adverse complication CPB surgery . Investigators hypothesize use increase adsorption membrane ( OXIRIS® ) CPB safe present low technical complexity . The safe use OXIRIS® reduce cytokine circulatory level lipopolysaccharide ( LPS ) circulatory level therefore decrease SIRS systemic effect specially concern renal function . Therefore , patient receive ( OXIRIS® ) could potentially present less postcardiac surgery acute kidney injury ( pAKI ) , low intensive care unit ( ICU ) hospital length stay , low production renal injury biomarkers ( cell-cycle-arrest-proteins ) tissue inhibitor metalloproteinase-2 ( TIMP-2 ) insulin growth factor bind protein-7 ( IGFBP-7 ) .</brief_summary>
	<brief_title>Clinical Trial Evaluate Use Adsorption Membrane ( OXIRIS® ) During Cardiopulmonary Bypass Surgery</brief_title>
	<detailed_description>Patients meet inclusion criterion would propose participate admitted cardiac presurgical ward . After informed consignment , patient randomize CPB-OXIRIS® , PrismafleX eXeed™ II ( Hospal ) OXIRIS® set irrigate saline preparation irrigation CPB circuit . PrismafleX eXeed™ II ( Hospal ) OXIRIS® set connect CPB circuit . Blood flow 150-200 ml/min derivatised CPB circuit PrismafleX eXeed™ flow OXIRIS® membrane . Flow , pressure alarm control PrismafleX eXeed™ independently CPB circuit . OXIRIS® membrane employ adsorption ( neither convection diffusion perform ) CPB time . Using CPB flow , patient require venous catheter access neither change CPB normal setting . All blood sample collect study obtain CPB circuit central venous catheter ( standard cardiac surgery protocol ) . During CPB time besides ordinary cardiac surgery assistance team , supplementary RRT expert team present patient randomize CPB-Oxiris . Blood sample variable equally collect register control group ( CPB-Standard ) modification CPB standard practice . Adverse event report ( less 24 hour severe ) sponsor center properly evaluate . If severe adverse event ( SAE ) finally evaluate study board relate intervention arm , urgent notification health authority must proceed study interrupted decision . Investigators warrant correct protocol application . Study data review external monitoring committee clinical assay research central unit ( UCICEC - IDIBELL ) . Monitors contrast register data collection data form ( CDF ) data patient´s medical record . All patient´s medical record indefinitely save electronical format review necessary . 1 . Registered variable follow-up . Renal function relate parameter . Plasma creatinine urine output register baseline , prior CPB , ICU admission , 6 hour ,12 hour , 24h postCBP every 24h first week cardiac surgery order evaluate postcardiac surgery acute kidney injury base AKIN criterion ( AKIN criterion Kidney inter.,2012 ; 2 : 1-138 . ) Urinary cell cycle arrest proteins TIMP-2 IGFBP-7 also quantify ICU admission . Renal function check hospital discharge . Inflammatory response parameter : Interleukin-1β ( IL-1β ) , tumor necrosis factor α ( TNF-α ) , monocyte chemotactic protein-1 ( MCP-1 ) , interleukin-6 ( IL-6 ) , interleukin-8 ( IL-8 ) , interleukin-10 ( IL-10 ) , interleukin-18 ( IL-18 ) , complement 5a ( C5a ) , high mobility bind protein 1 ( HMBP-1 ) , RANTES , oligodeoxyribonucleotide alfa ( GRO-alfa ) , leukocytes count , lactate , D-dimer , free plasma hemoglobin , HO-1 , free iron Lipopolysaccharide ( LPS ) level determine plasma . These determination measure baseline ( 0hours ) , time T1 ( end CPB ) , T2 ( ICU admission ) T3 ( 24hours ICU admission ) . Ordinary laboratory parameter : Plasmatic urea , potassium , albumin magnesium , phosphate , glucosa , sodium , chloride , Alanine transaminase ( ALT ) , aspartate aminotransferase ( AST ) , hemogram coagulation time determine follow ordinary cardiac surgery protocol ( every 8 hour first 24h ) . Clinical respiratory parameter : Hemodynamic respiratory parameter register every hour . Arterial venous gasometries arterial lactate determine every 8 hour first 24 hour . Temperature , heart rate , arterial blood pressure ( systolic , diastolic , mean ) , central venous pressure , vasopressor and/or inotrope dose register surgery ICU accord standard protocol . Demographic clinical record data : Age , gender , weight , height , relevant clinical record , previous chronic medication , type cardiac surgery , surgery time , time CPB , surgical complication , blood transfusion surgery , prognostic score ( SOFA , APACHE II SAPS II ) , ICU stay , hospital stay . Clinical outcome ( survival discharge , 28 90 day ) renal outcome ( renal function , RRT requirement ) . 2 . Techniques Lipopolysaccharide ( LPS ) LPS plasmatic concentration measure use Limulus amebocyte lysate ( LAL ) test ( Levin , J , et al . Thrombosis Et Diathesis Haemorrhagica . 1968 ; 19:186 ) . This technique perform LAL proteolytic factor activate LPS . Life Technologies kit use ( Thermo Fischer Scientific ) . NephroCheck® Commercial diagnostic kit base vitro fluorescence immunoassay technique order quantify TIMP-2 IGFBP-7 urinary biomarkers . Cytokines analysis IL-1 , IL-6 , IL-8 , IL-10 , IL-18 , TNFα , MCP-1 , HMBP-1 , RANTES , GROα quantification perform multiplex new technology . MILLIPLEX ( Millipore ) magnetic ball system use . 3 . Study Limitations SIRS harmful effect initiate CPB may persist surgery important limitation study evaluate use increase adsorption membrane CPB . However , investigator hypothesize important effect cytokine LPS level CPB observe . Furthermore , patient require non emergent cardiac surgery represent non absolutely homogeneous cohort could introduce potential bias main secondary objective . To avoid potential bias , temporary sequential randomization perform advanced chronic renal failure patient exclude . Cell cycle arrest protein , due test´s high cost , determine ( single check point ) ICU admission could also introduce temporary bias biomarkers could still undetectable urine sample . However , investigator think ICU admission probably important moment surgery order decide change clinical strategy could do base cell cycle arrest proteins value . 4 . Statistical analysis Missing data try avoid exhaustive patient´s follow study investigator . Data registry create include variable write individual data collection form ( DCF ) . Data bedside register study member final software database registration do statistic outside investigator contact patient situation . Cytokines LPS level introduce DCF measure . Statistical analysis do statistic investigator wont role patient´s selection , randomization , follow . SPSS v. 20.0 statistical analysis use . Variable distribution study logarithmic transformation use variable n't present normal distribution , presumably cytokine LPS level . Univariate analysis compare clinical , demographic , biochemical , metabolic , hemodynamic respiratory baseline variable arm ( CPB-OXIRIS® CPB-Standard ) , do two-tailed test continuous variable chi-square test categorical variable . Variables determine several time ( T0 , T1 , T2 , T3 ) analyse use one-way repeat measure ANOVA test order demonstrate difference arm . Multivariate analysis complete control clinically relevant confounding variable well discover baseline difference . Arm intervention ( CPB-OXIRIS® , CPB-Standard ) consider main independent variable add control independent variable . Intervention safety measure presence adverse effect related standard technique . This effect record CPB , CPB , first 24 hour postsurgery . As study measure cytokine LPS level four different moment ( T0 , T1 , T2 , T3 ) , order maximize statistical power reduce control variable number , area curve ( AUC ) we´ll determine every cytokine LPS first 24 hour . Due statistical maneuver investigator obtain continuous variable represent cytokine-LPS level biochemical study period ( 24 hour ) . To evaluate arm intervention improvement term efficacy safety could relate cytokine and/or LPS level first 24 hour , mediation complementary analysis do consider cytokine-LPS ( represent AUC ) mediator independent variable ( intervention arm ) effect study .</detailed_description>
	<criteria>Patients 18 year old . Non emergent cardiac surgery require CPB . Written informed consent patient legal surrogate Immunosuppressive treatment steroid ( prednisone &gt; 0.5 mg/kg/day equivalent ) . Autoimmune disorder . Transplant receptor . Advanced Chronic Kidney Disease ( CKD 4 5 ) . Renal replacement therapy ( RRT ) last 90 day . Documented intolerance study device . Inclusion ongoing study within last 30 day . Pregnancy . Coexisting illness high probability death ( inferior 6 month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>CPB</keyword>
	<keyword>OXIRIS®</keyword>
	<keyword>SIRS</keyword>
	<keyword>AKI</keyword>
	<keyword>Cytokines</keyword>
	<keyword>LPS</keyword>
</DOC>